Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

NCT ID: NCT06141889

Last Updated: 2024-02-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-17
• Study Completion Date: 2024-02-02

Brief Summary

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers.

Detailed Description

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers. The study will enroll approximately 16 participants.

Conditions

Healthy Volunteer Study

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single dose, 2-way crossover in Part 1, then daily dosing for 14 days in Part 2

Study Part 1:

Participants will receive a single Dose A or B on Day 1 and then followed by a crossover to a single Dose B or A on Day 8.

Study Part 2:

Participants in Study Part 2 will receive either a single Dose C or equivalent of Dose C administered twice daily, starting on Day 1 and through Day 14

Group Type: EXPERIMENTAL

Azelaprag

Intervention Type: DRUG

oral, apelin receptor (APJ) agonist

Interventions

Azelaprag

oral, apelin receptor (APJ) agonist

Intervention Type: DRUG

Other Intervention Names

BGE-105

Eligibility Criteria

Inclusion Criteria

1. Healthy male or female volunteers ≥ 60 years of age

2. No history or evidence of clinically relevant medical disorders

3. Body mass index (BMI) between 18 and 40 kg/m2

4. Acceptable physical examination findings, including vital signs, and electrocardiogram (ECG)

5. Acceptable clinical laboratory values

6. Female participants of non-childbearing potential

Exclusion Criteria

1. Currently receiving treatment with another investigational drug or investigational device within 30 days (or 5 half-lives, whichever is longer)

2. Current or previous malignancy within 5 years, with the exception of non-melanoma skin cancers, cervical or breast ductal carcinoma in situ, or adenocarcinoma of the prostate

3. Positive test result for COVID (rapid test), human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibodies

4. Use of any medications that might affect the metabolism of the study drug as assessed by the Investigator and Sponsor and use of any herbal supplements, vitamins, or nutritional supplements within the 14 days prior to the dose day of each dosing period or during study participation.

5. Planned elective surgery within 30 days prior to Screening, during the study period or before the participant's red blood cell (RBC) have returned to normal levels

6. Systolic blood pressure > 150 mm Hg or < 90 mm Hg or diastolic blood pressure > 95 mm Hg or < 60 mm Hg

7. Unwilling or unable to abstain from the use of nicotine or tobacco containing products (including but not limited to snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) or the use of cannabis or marijuana

8. Positive urine drug screen or alcohol breath test at screening and/or known history of drug or alcohol abuse within 1 year prior to screening

9. History or evidence of any other clinically significant disorder, condition, or disease, that, in the opinion of the investigator or Sponsor medical monitor, if consulted, would pose a risk to participant safety, or interfere with the study evaluation, procedures, or completion

10. Concurrent or previous use of aspirin within 14 days and NSAIDs within 3 days before the dose day of each dosing period.

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

BioAge Labs, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Patrick Martin, MD

Role: STUDY_DIRECTOR

BioAge Labs, Inc.

Locations

New Zealand Clinical Research

Auckland, , New Zealand

Countries

New Zealand

Other Identifiers

BGE-105-004

Identifier Type: -

Identifier Source: org_study_id